Image

Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation

Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.

Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.

Description

Glaucoma is a chronic progressive optic neuropathy characterized by irreversible visual field loss. Reduction of intraocular pressure (IOP) remains the only evidence-based strategy to slow disease progression. Micropulse transscleral cyclophotocoagulation (MP-CPC) has become an increasingly used laser modality due to its favorable safety profile compared to continuous-wave cyclophotocoagulation.

Despite demonstrated efficacy, the magnitude and durability of the hypotensive effect after MP-CPC vary considerably among patients. Identification of structural ocular biomarkers associated with treatment response may improve patient selection and enable a more individualized therapeutic approach.

The choroid plays a key role in ocular blood flow regulation and may influence aqueous humor dynamics, particularly uveoscleral outflow. Variations in choroidal thickness may reflect differences in vascular reactivity, tissue compliance, and structural characteristics that could modulate the biological response to laser energy.

This prospective study will include patients with various types of glaucoma scheduled to undergo MP-CPC. Subfoveal choroidal thickness and the choroidal vascularity index (CVI) will be measured using enhanced depth imaging optical coherence tomography (EDI-OCT) at three time points: Preoperatively (baseline), 3-7 days after MP-CPC, 1 month after MP-CPC Intraocular pressure will be assessed at the same time points using Corvis ST tonometry.

The primary objective of the study is to evaluate the correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction at early (3-7 days) and short-term (1 month) follow-up.

Secondary objectives include: Assessment of dynamic changes in choroidal thickness after MP-CPC, Evaluation of the relationship between baseline choroidal thickness and the degree of IOP reduction, Determination of a threshold (minimal) baseline choroidal thickness associated with a clinically significant hypotensive response, Safety evaluation, including changes in visual acuity and postoperative complications Correlation and regression analyses will be performed to determine whether baseline choroidal thickness and its early postoperative changes can predict the degree and stability of IOP reduction.

The identification of morphometric predictors of MP-CPC efficacy may contribute to the development of personalized treatment algorithms and improve prognostic stratification in patients undergoing laser management of glaucoma.

Eligibility

Inclusion Criteria:

  • Decision to treat by MP-CPC Laser
  • Patients diagnosed with Glaucoma
  • Patients aged 18 years old and above
  • Glaucoma that is inadequately controlled on medical therapy

Exclusion Criteria:

  • Patients age less than 18 years
  • Patients unable or unwilling to provide informed consent to participate in the study
  • Patients potentially unavailable for follow up visits
  • Patients with significant scleral thinning
  • Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study
  • Albino patients that have no iris pigmentation

Study details
    Glaucoma

NCT07592923

Kazakh Eye Research Institute

27 June 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.